ABSTRACT
Objective To explore the effect of LncRNA HOXD-AS1 on the radiosensitivity of H460 cells by targeting the regulation of miR-454-3p expression. Methods H460 cells were irradiated with 0, 2, 4, 6 and 8 Gy, and the expression levels of HOXD-AS1 and miR-454-3p were detected by qRT-PCR. Cell apoptosis rate were measured by flow cytometry experiments. Cell cloning experiments were used to detect cell radiosensitivity. The protein expression levels of Caspase-3, Cyclin D1 and γ-H2AX were detected by Western blot. Results The expression of HOXD-AS1 in H460 cells was significantly increased after X-ray irradiation ( P<0.05) , while the expression of miR-454-3p was significantly decreased ( P<0.05) . Silencing HOXD-AS1 significantly promoted apoptosis, increased radiosensitivity of lung cancer cells, promoted Caspase-3, γ-H2AX protein expression, and inhibited Cyclin D1 expression. HOXD-AS1 could target the expression of miR-454-3p. Conclusion Silencing HOXD-AS1 can promote the apoptosis of lung cancer cells and inhibit cell survival by targeting miR-454-3p to increase the radiosensitivity of lung cancer cells.
ABSTRACT
Objective To investigate the effect of body mass index (BMI) on the clinical efficacy and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD), and to provide evidence for the use of BMI in predicting their disease situation and prognosis.Methods Eighty patients with AECOPD admitted to the Department of Respiration of the Fourth Central Hospital of Tianjin from October 2014 to October 2015 were enrolled, and they were divided into low BMI group (BMI < 18.5 kg/m2) and normal BMI group (BMI 18.5 - 24.9 kg/m2) by difference in BMI. The differences in body height, body weight, blood gas analysis indexes [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)], lung function indexes [the percentage of the first second forced vital capacity/predicted value (FEV1%), the ratio of the first second forced vital capacity/forced vital capacity (FEV1/FVC)], hospitalization time, recurrence time and smoking index were compared between the two groups, the correlations between BMI and the indexes of blood gas analysis, pulmonary function, hospitalization time, recurrence time and smoking index in low BMI group were analyzed.Results The BMI (kg/m2: 21.09±2.03 vs. 16.39±1.26), PaO2 [mmHg (1 mmHg = 0.133 kPa): 63.59±4.95 vs. 56.54±3.23], FEV1% [(64.18±3.82)% vs. (59.82±5.73)%] and FEV1/FVC (63.83±3.20 vs. 59.28±3.63) in normal BMI group were all significantly higher than those in the low BMI group, PaCO2 in normal BMI group was significantly lower than that in the low BMI group (mmHg: 57.05±5.25 vs. 63.70±7.29). The results indicated that the patients in low BMI group had severer hypoxia and carbon dioxide retention than those in normal BMI group, and the lung function was also worse than that in the normal BMI group; the hospitalization time of normal BMI group was shorter than that of low BMI group (days: 11.70±2.36 vs. 15.25±2.80), and the recurrence time in normal BMI group was obviously longer than that of low BMI group (days: 93.78±57.85 vs. 48.58±17.85), smoking index in normal BMI group was markedly lower than that of low BMI group (year·branch: 2550.0±917.6 vs. 3652.5±1015.8), the differences were statistically significant (allP < 0.05). The linear correlation analyses showed that: BMI in low BMI group was positively correlated with PaO2, FEV1% and recurrence time (r = 0.557, 0.507, 0.455,P = 0.000, 0.000, 0.003), and was negatively correlated with PaCO2, hospitalization time and smoking index (r = -0.670, -0.405, -0.440,P = 0.009, 0.000, 0.005), and had no significant correlation with FEV1/FVC (r = 0.061,P = 0.707).Conclusion BMI is an important index for evaluating the severity and prognosis of patients with AECOPD.
ABSTRACT
Objective To investigate the application value of combination of ambroxol and fluidmicronized ipratropium bromide in full dose and frequency in treating senile refractory pneumonia.Methods From January 2010 to November 2013,84 cases of elderly patients with refractory pneumonia were divided into 3 groups.On the basis of anti-inflammatory and symptomatic treatment,the control group (n=28) received routine sputum suction and normal saline irrigation;the routine dose group (n=28) received the intravenous ambroxol 15 mg twice daily and the inhalation of 2.5 ml of nebulized ipratropium bromide once daily plus treatment in control group while full dose group (n=28) received intravenous ambroxol hydrochloride 30 mg three times a day and the inhalation of 2.5 ml of nebulized ipratropium bromide four times a day.The severity of pulmonary infection was described by clinical pulmonary infection score (CPIS) and C reactive protein (CRP),and therapeutic efficiency was evaluated by clinical symptom remission time,average hospitalization days and effective rate.Results At the 5 day and 10 days after treatment,the CPIS in full dose group was (4.82 ± 1.21) scores and (4.39± 1.03),respectively,C-reactive protein (CRP) was (58.11 ± 11.12) mg/L and (57.57±12.69) mg/L respectively,and these CPIS and CRP values at the 5 day and 10 days were significantly lower than those in the control group (6.10 ± 1.10) scores and (5.36 ± 0.95) scores,(74.50± 12.79)mg/L and (68.46± 13.77) mg/L (all P＜0.05).The above Values were lower as compared with those [(5.43±0.84) and (5.21 ±0.83),(65.11 ±834) mg/L and (59.11± 13.77) mg/L (P＜ 0.05)] in routine dose group.The CPIS and CRP concentration in full dose group and routine dose group were lower at the 10 days than at the 5 days (P＜0.05).Besides,clinical symptom remission time (4.43 ± 1.75) days,average hospitalization duration(26.32 ± 4.92) days in full dose group,clinical symptom remission time (5.68 ± 2.29) day,average hospitalization (32.21 ± 5.63) days in conventional dose group were significantly lower than in the control group (7.79±2.74) and (36.71 ± 11.78) days (P ＜ 0.05).Clinical manifestation,time of remission,and average hospitalization days of the full dose group were also reduced as compared with the conventional dose group (P＜0.05).The efficiency rates in the three groups of control,conventional dose and full dose were 42.9％ (12/28),71.4％ (20/28),92.9％ (26/28),among which the efficiency of full dose group was significantly higher than those of the control group and the conventional dose group,(x2 =16.047,6.788,P＜0.01).The conventional dose group showed a higher efficiency than the control group (x2 =4.667,P ＜ 0.01).Conclusions Combination of ambroxol and fluid-micronized ipratropium bromidet in full dose and frequency for treating senile refractory pneumonia is a useful managemen in the elderly patients.
ABSTRACT
Objective To observe the clinical effects of ambroxol on acute stroke-associated pneumonia (SAP).Methods From July 2011 to December 2012,a total of 82 patients with strokeassociated pneumonia (SAP) admitted to our hospital were selected and randomly divided into ambroxol group (n=43,treated with ambroxol in combination with antibiotic therapy) and control group (n =39,treated with antibiotic therapy).The defervescence time,hospitalization time,antibiotic use time,C-reactive protein level,blood oxygen partial pressure,bacterial clearance rate and the total effective rate were compared between the two groups.Results The defervescence time,hospitalization time,antibiotic use time were shorter in ambroxol group than in control group [(3.1 ± 0.8)d vs.(3.8±1.1)d,(11.7±3.7)d vs.(13.6±4.9)d,(5.4±1.7)dvs.(6.6±2.1)d,t=18.60,22.80,23.50,P=0.014,0.008,0.011,repectively].Bacterial clearance rate and the total effective rate were higher in ambroxol group than in control group [90.7％ vs.74.4％,93.0％ vs.74.4％,x2 =3.86,5.34,P=0.05,0.02].There were no significant differences in changes of C-reactive protein level and blood oxygen partial pressure between two groups before and after treatment (all P＞0.05).Conclusions Ambroxol is an effective treatment for acute stroke associated pneumonia,which can shorten antibiotic use time and duration of symptoms and remove bacteria effectively.